Andexanet alfa is approved for patients taking apixaban or rivaroxaban who require reversal of anticoagulation due to life-threatening or uncontrolled bleeding.Availability of these agents improves the overall safety of direct oral anticoagulants. The US Food and Drug Administration has approved specific antidotes for apixaban, rivaroxaban, and dabigatran.Direct oral anticoagulants, including apixaban, rivaroxaban, edoxaban, betrixaban, and dabigatran, have many advantages over warfarin, yet patients are still at risk for hemorrhagic events.The following are key points to remember about this review of andexanet alfa for reversing the anticoagulant effects of apixaban or rivaroxaban:
0 kommentar(er)
